Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label dose-escalation and expansion study of CTS2190 in advanced solid tumors
CTR20231385Phase 2Active
- Sponsor
- Sailan Bio
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CTS2190 in Nonhematologic neoplasms, sponsored by Sailan Bio. Primary endpoints: Dose-limiting toxicity incidence during the DLT evaluation period, Treatment-emergent adverse events and serious adverse events and 3 more. Started Jun 2023; status: active.
02
Drugs
CTS2190
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20231385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231385.